Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from pharmacy benefit managers. The organizations are often creating obstacles to coverage, such as steep cost restrictions and approval processes that hinder patient opp… Read More